martedì, 25 giugno 2024
1 Settembre 2017

FDA Approves Frontline Fulvestrant for HR-Positive/HER2-Negative Breast Cancer

August 28, 2017 – The FDA has approved fulvestrant for use in hormone receptor (HR)-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The approval is based on results from the phase III FALCON trial, which showed that fulvestrant extended median progression-free survival (PFS) by 2.8 months compared with the aromatase inhibitor anastrozole (16.6 vs 13.8 … (leggi tutto)